Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Public ClinicalTrials.gov record NCT05150587. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIa, Multicenter, Double Blind, Placebo Controlled, Randomized Clinical Trial to Assess Safety, Efficacy and Pharmacokinetics of Rifaximin Delayed-Release (Rifaximin-EIR) in Patients With Moderate-to-severe Papulopustular Rosacea
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Rosacea is a common chronic inflammatory relapsing-remitting skin condition almost exclusively affecting the central area of the face and the eyes. Preliminary evidence suggests that treatment with rifaximin, a poorly absorbed oral antibiotic drug may be beneficial in patients with rosacea, particularly in those with papulopustular phenotype and positivity to Lactulose Breath Test (L-BT). The objective of this study is twofold: 1. To explore the safety and efficacy of 2 doses of oral Rifaximin versus placebo in adults with moderate-to-severe papulopustular rosacea. 2. To assess the pharmacokinetics (PK) of these two dose regimens in a sub-group of patients.
Study identification
- NCT ID
- NCT05150587
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 5, 2021 (Actual)
- Primary completion
- Oct 20, 2022 (Actual)
- Completion
- Oct 20, 2022 (Actual)
- Last update posted
- Apr 24, 2024
2021 – 2022
United States locations
- U.S. sites
- 38
- U.S. states
- 19
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dermatology Research Ventures | Yuma | Arizona | 85365 | — |
| Johnson Dermatology | Fort Smith | Arkansas | 72916 | — |
| Long Beach Clinical Trials | Long Beach | California | 90806 | — |
| Metropolis Dermatology | Los Angeles | California | 90017 | — |
| LA Universal Research Center | Los Angeles | California | 90057 | — |
| Cosmetic Laser Dermatology | San Diego | California | 92121 | — |
| UCSD | San Diego | California | 92122 | — |
| University Clinical Trials, Inc. | San Diego | California | 92123 | — |
| Skin Care Research | Boca Raton | Florida | 33486 | — |
| MOORE Clinical Research,Inc. | Brandon | Florida | 33511 | — |
| Sweet Hope Research Specialty, Inc. | Hialeah | Florida | 33016 | — |
| Savin Medical Group | Miami Lakes | Florida | 33014 | — |
| Leavitt Medical Associates of Florida | Ormond Beach | Florida | 32174 | — |
| DelRicht Research | Marietta | Georgia | 30060 | — |
| DS Research | Clarksville | Indiana | 47129 | — |
| Skin Science PLLC | Louisville | Kentucky | 401217 | — |
| DS Research | Louisville | Kentucky | 40241 | — |
| Delricht Research Baton Rouge LA | Baton Rouge | Louisiana | 70809 | — |
| Delricht Research Covington LA | Covington | Louisiana | 70433 | — |
| DelRicht Research Houma Louisiana | Houma | Louisiana | 70360 | — |
| DelRicht Research | New Orleans | Louisiana | 70115 | — |
| Revival Research Institute, LLC. | Troy | Michigan | 48084 | — |
| Grekin Skin Care Institute | Wyandotte | Michigan | 48192 | — |
| MediSearch Clinical Trials | Saint Joseph | Missouri | 65406 | — |
| JDR Dermatology Research | Las Vegas | Nevada | 89148 | — |
| JUVA Skin and Laser Center | New York | New York | 10022 | — |
| Onsite Clinical Solutions | Charlotte | North Carolina | 28277 | — |
| Dermatology Consulting Services, PLLC | High Point | North Carolina | 27262 | — |
| DelRicht Research | Tulsa | Oklahoma | 74114 | — |
| Oregon Dermatology and Research Center | Portland | Oregon | 97210 | — |
| Paddington Testing Co, Inc | Philadelphia | Pennsylvania | 19103 | — |
| Dermatology Treatment and Research Center | Dallas | Texas | 75230 | — |
| 3A Research | El Paso | Texas | 79925 | — |
| DelRicht Research Frisco Texas | Frisco | Texas | 75034 | — |
| Austin Institute for Clinical Research | Pflugerville | Texas | 78660 | — |
| Progressive Clinical Research | San Antonio | Texas | 78213 | — |
| Velocity Clinical Research | Salt Lake City | Utah | 84117 | — |
| West End Dermatology Associates | Richmond | Virginia | 23233 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05150587, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 24, 2024 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05150587 live on ClinicalTrials.gov.